# A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

> **NCT00386555** · PHASE2 · WITHDRAWN · sponsor: **Arog Pharmaceuticals, Inc.**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** docetaxel
- **DRUG:** CP-868,596 + docetaxel
- **DRUG:** AG-013736 + docetaxel
- **DRUG:** CP-868,596 + AG-013736 + docetaxel

## Key facts

- **NCT ID:** NCT00386555
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was cancelled before patient enrollment
- **Last updated:** 2012-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386555, "A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00386555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*